BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cholestatic Liver Disease readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Cholestatic Liver Dis
 ease\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06730061-1262@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Iqirvo (Elafibranor): Phase 3 readout est. (NCT06730061)
DESCRIPTION:Iqirvo (Elafibranor)\, phase 3\, Primary Biliary Cholangitis.\n
 Study: A Study of Elafibranor in Adult Japanese Participants With Primary 
 Biliary Cholangitis (PBC)\nEstimated primary completion: 17 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/elafibranor#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06730061
URL:https://assetmemo.bio/drug/elafibranor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05050136-10898@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:volixibat: Phase 2 readout est. (NCT05050136)
DESCRIPTION:volixibat\, phase 2\, Primary Biliary Cholangitis.\nStudy: A St
 udy to Evaluate Efficacy and Safety of an Investigational Drug Named Volix
 ibat in Patients With Itching Caused by Primary Biliary Cholangitis\nEstim
 ated primary completion: January 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/volixibat#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05050136
URL:https://assetmemo.bio/drug/volixibat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06427395-1111@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20270418
DTEND;VALUE=DATE:20270419
SUMMARY:Lipaglyn (Saroglitazar): Phase 3 readout est. (NCT06427395)
DESCRIPTION:Lipaglyn (Saroglitazar)\, phase 3\, Primary Biliary Cholangitis
 .\nStudy: Open-Label Extension Study of Saroglitazar Magnesium in Particip
 ants With Primary Biliary Cholangitis\nEstimated primary completion: 18 Ap
 ril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/saroglitaza
 r#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 427395
URL:https://assetmemo.bio/drug/saroglitazar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07424677-1111@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Lipaglyn (Saroglitazar): Phase 3 readout est. (NCT07424677)
DESCRIPTION:Lipaglyn (Saroglitazar)\, phase 3\, Primary Biliary Cholangitis
 .\nStudy: Study of Saroglitazar Magnesium for PBC Patients With Incomplete
  Response or Intolerant to UDCA Therapy\nEstimated primary completion: Jul
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/saroglitazar#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0742
 4677
URL:https://assetmemo.bio/drug/saroglitazar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03301506-1117@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Livdelzi (Seladelpar): Phase 3 readout est. (NCT03301506)
DESCRIPTION:Livdelzi (Seladelpar)\, phase 3\, Primary Biliary Cholangitis.\
 nStudy: Study of Seladelpar in Participants With Primary Biliary Cholangit
 is (PBC)\nEstimated primary completion: November 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/seladelpar#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03301506
URL:https://assetmemo.bio/drug/seladelpar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07841977-1117@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Livdelzi (Seladelpar): Phase 2 readout est. (NCT07841977)
DESCRIPTION:Livdelzi (Seladelpar)\, phase 2\, Primary Biliary Cholangitis.\
 nStudy: Study of Seladelpar and Cilofexor in Participants With Primary Bil
 iary Cholangitis\nEstimated primary completion: December 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/seladelpar#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07841977
URL:https://assetmemo.bio/drug/seladelpar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06016842-1262@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Iqirvo (Elafibranor): Phase 3 readout est. (NCT06016842)
DESCRIPTION:Iqirvo (Elafibranor)\, phase 3\, Primary Biliary Cholangitis.\n
 Study: A Long-Term Study of Elafibranor in Adult Participants With Primary
  Biliary Cholangitis\nEstimated primary completion: 31 May 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/elafibranor#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06016842
URL:https://assetmemo.bio/drug/elafibranor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06051617-1117@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Livdelzi (Seladelpar): Phase 3 readout est. (NCT06051617)
DESCRIPTION:Livdelzi (Seladelpar)\, phase 3\, Primary Biliary Cholangitis.\
 nStudy: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and 
 Compensated Cirrhosis\nEstimated primary completion: August 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/seladelpar#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06051617
URL:https://assetmemo.bio/drug/seladelpar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07216235-1111@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Lipaglyn (Saroglitazar): Phase 3 readout est. (NCT07216235)
DESCRIPTION:Lipaglyn (Saroglitazar)\, phase 3\, Primary Biliary Cholangitis
 .\nStudy: Long-Term Study to Evaluate the Safety and Efficacy in Participa
 nts With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinic
 al Outcomes\nEstimated primary completion: November 2032. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/saroglitazar#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07216235
URL:https://assetmemo.bio/drug/saroglitazar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
